MarketVIEW Travel Vaccines  ·  2026 Edition  ·  Now Available to Order

New Travel Vaccines -
Segment Forecast to 2040

Travel vaccination data per indication is one of the hardest datasets in vaccine intelligence to quantify - most vaccines carry dual endemic, schedule and travel use, and no manufacturer reports revenue by setting. We built a methodology to solve it. The 2026 edition de-layers 13 marketed travel vaccines out of their wider franchises across 13 origin markets - 169 country-level cells, each anchored to disclosed company actuals where they exist, apportioned by pathogen-specific outbound travel and graded for confidence. Bottom-up, not a top-down guess.

2026 Edition · Now Available to Order 169 Anchored Country-Level Cells 13 Marketed Vaccines De-layered 14 Origin Countries Three IATA-Anchored Scenarios to 2040 Primary Traveller Survey
Product catalogue
VAMV090
2026 edition · now available to order

Format
PDF + 2 Excel workbooks
Presentation slides
>300 slides
Origin countries
14
Marketed vaccines de-layered
13
Country-level cells
169, confidence-graded
New vaccine products
9
Forecast horizon
To 2040, three scenarios
Survey included
Yes (2023 wave)
Edition
2026
Availability
Now available to order
169
Country-level cells, each
anchored and confidence-graded
13
Marketed travel vaccines
de-layered from their franchises
9
New vaccine products
forecast to 2040
5.2bn
Air passengers forecast
worldwide in 2026, a record
Travel vaccine landscape

The unique challenge of travel vaccine intelligence

Travel medicine sits at the intersection of infectious disease epidemiology, public health policy and commercial vaccine strategy. Understanding the true travel-specific demand for each vaccine - separate from endemic and routine schedule use - requires a purpose-built analytical approach.

CDC · IHR 2005 · WHO · peer-reviewed sources

Travel vaccination - indication landscape and regulatory context

Vaccinations are pivotal in travel medicine because of the potential for travellers to be exposed to pathogens outside their home country - whether as Visiting Friends and Relatives (VFR), business travellers, or leisure tourists. Health authorities including the US Centers for Disease Control and Prevention (CDC) recommend a pre-travel review of both routine and travel-specific vaccines according to destination, trip characteristics and personal health status.

Certain vaccines carry a mandatory requirement under the International Health Regulations (IHR), 2005 and are required for entry to specific countries or regions: yellow fever is mandatory for travel to or from defined yellow fever zones; meningococcal vaccines are required for Hajj pilgrimage; and oral polio vaccine documentation is required for travellers from polio-endemic nations. Beyond mandatory vaccines, a substantial and growing list of vaccines is recommended for specific destination-traveller combinations.

The commercial complexity of the travel vaccine market arises from the dual-use nature of many products. Hepatitis A, Hepatitis B, typhoid, rabies and Japanese encephalitis vaccines are used in both endemic public health programmes and routine schedule contexts - as well as in pre-travel clinics. Quantifying the travel-specific revenue contribution requires a methodology that goes well beyond simple company-reported figures, which do not disaggregate by indication or setting of use. This methodological challenge is precisely why robust independent travel vaccine market data is so scarce - and why VacZine Analytics developed a proprietary approach for this report.

The typhoid segment had a policy update within this window: in August 2026, WHO published a revised position paper on typhoid vaccines (Weekly Epidemiological Record, 18 August 2026), its first substantive update since 2018, incorporating new evidence on typhoid conjugate vaccine (TCV) effectiveness, duration of protection and antimicrobial-resistant Salmonella Typhi. The update sets the global policy backdrop against which pre-travel typhoid vaccination guidance, and the marketed Typhim Vi franchise, will now be read.

The yellow fever segment also had a policy update in this window: at its 5-8 October 2026 meeting, WHO's Strategic Advisory Group of Experts on Immunization (SAGE) concluded that a fractional, one-fifth dose of yellow fever vaccine produces a non-inferior immune response to the standard dose in people aged 2 and above, and recommended that fractional dosing may be used not only in outbreak response but also in preventive campaigns for ages 2 to 59 where vaccine supply or financing would otherwise limit coverage - routine and catch-up childhood vaccination should continue on the standard dose. Yellow fever is the IHR 2005 vaccine most directly anchoring this segment's mandatory-vaccine modelling, so any shift in dosing policy carries through to destination-level demand assumptions.

The 2026 edition carries this through to the products now arriving: dengue (Qdenga) and chikungunya (IXCHIQ, Valneva VAL-1553) have moved from pipeline to marketed and are modelled as such, while ETEC/traveller's diarrhoea (ETVAX), Lyme disease, Zika, Campylobacter, Shigella, norovirus and malaria sit in the new-product forecast set. Each will add complexity and cost to pre-travel decision-making across the forecast period, and each competes for the same finite consultation time and traveller willingness to pay.

Yellow Fever ⚠ mandatory Meningococcal (Hajj) ⚠ mandatory Hepatitis A Hepatitis B Typhoid fever Rabies Japanese Encephalitis Cholera / ETEC Dengue (Qdenga / IXCHIQ) Chikungunya (IXCHIQ) ETEC (ETVAX) Tick-borne Encephalitis Lyme disease COVID-19 (travel context)

⚠ Mandatory = required under IHR 2005 or destination country entry requirements. New = recently approved or within-registration at time of publication. Emerging = late-stage pipeline with travel-relevant indication.

The VacZine Analytics travel vaccine methodology

Why travel vaccine data is uniquely hard - and how we solved it

Most travel vaccine products are sold through the same supply chain that serves endemic public health programmes and routine schedule use. No manufacturer reports revenues disaggregated by indication or clinical setting. Standard market research approaches fail here: surveillance data captures doses administered, not the setting; IMS/IQVIA pharmacy data cannot distinguish a travel clinic from a GP surgery. VacZine Analytics developed a novel, multi-source triangulation methodology combining country-level travel statistics, pre-travel clinic consultation data, disease epidemiology in destination regions and a primary consumer survey of prospective travellers (2023 wave, carried into the 2026 edition) to quantify travel-specific vaccine demand per indication. The 2026 edition takes this further by anchoring each country-level cell to disclosed company actuals where they exist and grading every cell for confidence. The result is a dataset that does not exist anywhere else in the public domain.

Inside the 2026 edition

The whole arc of the travel vaccine market, in one analysis

The 2026 edition is a bottom-up rebuild of the marketed travel vaccine market, sitting alongside the new-product forecasts. Travel-attributed sales are separated cleanly from endemic and routine use, so the traveller market can finally be read on its own terms rather than inferred from franchise totals.

169Country-level cells

Every vaccine, in every market, built cell by cell

Each of the 13 marketed travel vaccines is split across 13 origin markets, giving 169 country-level estimates. Each is anchored to disclosed company actuals where they exist, then apportioned by pathogen-specific outbound travel. Not a top-down guess - a bottom-up build.

13Vaccines de-layered

Travel demand lifted out of the franchise

Cholera and ETEC, hepatitis A and B, meningococcal ACWY, Japanese encephalitis, rabies, tick-borne encephalitis, typhoid, yellow fever, chikungunya and dengue - each de-layered from the wider franchise that also serves endemic programmes and routine schedules.

13Origin markets

The outbound markets that actually pay

US and Canada, the UK, EU5, the Nordics, Japan, South Korea and Australia are modelled individually within the wider 14-country origin set, because pre-travel vaccination practice, reimbursement and clinic infrastructure differ sharply between them.

WeightedBy destination, not by population

Where travellers actually go

Each vaccine is weighted by destination-specific outbound travel rather than headline departure counts: rabies-endemic regions, Japanese encephalitis in rural Asia, the meningitis belt plus Hajj and Umrah pilgrimage. Risk, not just volume, drives the demand estimate.

GradedConfidence made explicit

You can see how sure we are

Every cell carries a confidence grade, so a figure anchored to a disclosed company actual is never presented with the same weight as a modelled apportionment. Buyers can stress-test the parts of the model that matter to their own decision.

LicensedLabel footprint mapped

Revenue only where a product can be sold

Revenue is allocated only where a product is actually licensed. A traffic-light availability map captures traveller-market availability across every modelling country - and the newer franchises, chikungunya and dengue, carry the sharpest restrictions.

Travel demand outlook · Q1 2026

The addressable traveller population is at a record high

307MInternational arrivals in Q1 2026, up 2 percent year on year
5.2bnAir passengers forecast for full-year 2026, up 4.4 percent
83.8%Forecast load factor, an unprecedented level
3-4%Full-year 2026 arrivals growth, moderating from 2025

Forecast demand in this report is anchored to IATA air passenger projections rather than to generic tourism growth, and runs as three scenarios to 2040 - high, base and low, spanning a 2.9 to 3.3 percent CAGR band. That matters because the traveller base is no longer recovering, it is setting records: full-year 2026 is forecast at 5.2 billion air passengers on a forecast $41 billion industry net profit.

It also matters because the growth is not frictionless. Regional conflict is estimated to have taken 1 to 2 percentage points off 2026 arrivals growth, and IATA names five structural risks - geopolitical fragmentation, supply chain and aircraft delivery backlogs not clearing before the early 2030s, climate disruption, cyber threats and macroeconomic uncertainty. For travel vaccine demand the effect is less about the total shrinking than about corridors shifting: destination substitution moves demand between pathogen risk profiles, and capacity constraints favour premium long-haul routes, which are exactly the trips that trigger a full pre-travel consultation.

Competitive landscape

Major players & the new mid-tier challengers

The travel vaccine market has historically been dominated by the major vaccine groups, but a new wave of specialist mid-tier players is now reshaping competitive dynamics - particularly in the new indication pipeline.

Major player
Sanofi Pasteur

Broad travel vaccine portfolio including typhoid (Typhim Vi), hepatitis A/B, rabies and yellow fever. Key position in the adult and paediatric travel market across all 14 origin countries.

Major player
GSK

Hepatitis A/B (Twinrix), typhoid, rabies and Japanese encephalitis programmes. Also advancing mRNA programme with potential future travel implications.

Major player
Merck & Co

Travel-relevant hepatitis and typhoid products alongside newer dengue portfolio via Qdenga licensed through Takeda. Key US market position.

Growing mid-tier
Valneva SE

The fastest-growing specialist. IXCHIQ (chikungunya) -first-ever approved chikungunya vaccine. VAL-1553 programme and Japanese encephalitis franchise (IXIARO/JESPECT). Strategically focused on travel indications. The UK's MHRA revoked IXCHIQ's marketing authorisation in October 2026 following a further Commission on Human Medicines benefit-risk review of the travel vaccine - Valneva says the decision is not linked to any newly identified safety signal and does not affect its licences in the EU, Canada, Brazil or other current markets. On 10 November 2026, Valneva reported that 94% of IXCHIQ recipients retained seroresponse five years after a single dose, consistent with earlier persistence readouts at 12 and 24 months and three years and a previously reported 95% at four years, reinforcing the vaccine's single-dose durability profile. A day earlier, the company reported positive Phase 2 results - an infant immunogenicity and safety trial and a controlled human infection model study - for its tetravalent Shigella vaccine candidate S4V2, citing a favourable safety profile and encouraging immunogenicity and efficacy signals as it evaluates the full dataset to determine next steps.

Growing mid-tier
Bavarian Nordic

Significant recent acquisitions in the travel space. VIMKUNYA (chikungunya) picked up Health Canada approval in June 2026 - its fifth global approval after the US, EU, UK and Switzerland - followed by a Brazil filing with partner Eurofarma in July 2026. Expanding portfolio addresses dengue, chikungunya and other travel-relevant pathogens. Strategic intent to build a travel vaccine specialist position.

Emerging
Pfizer & others

Pfizer/Valneva's VLA15 (Lyme disease) is the most advanced near-term entrant: Phase 3 VALOR data (Mar 2026) showed ~74% efficacy, and the EU marketing authorisation application was validated by the EMA in August 2026. The ETVAX partnership (ETEC/traveller's diarrhoea) and other late-stage candidates follow, alongside earlier Zika, Campylobacter, Shigella, norovirus and malaria programmes with travel-relevant potential.

Scope of analysis

Six layers - one complete travel market picture

The VAMV090 analysis combines the proprietary travel demand methodology and the 169-cell marketed-vaccine build with a full competitive review, 9 new vaccine forecasts and primary consumer research - in a format that goes far beyond any publicly available travel medicine data.

🌍
14-country demand model

Travel vaccine demand modelled from 14 origin countries across North America, Europe and Asia-Pacific, with 13 of them carrying the full 169-cell marketed-vaccine build. Volume and value outputs by origin country and traveller type.

🔬
Proprietary travel demand methodology

The core innovation of this report: a multi-source triangulation methodology that isolates the travel-specific component of each vaccine's demand from endemic and schedule use. This dataset does not exist elsewhere.

💬
Primary traveller survey

Consumer primary research with prospective travellers to endemic regions (2023 wave, carried into the 2026 edition). Assesses awareness of endemic diseases, attitudes to vaccination and willingness to accept new travel vaccines, including dengue and chikungunya.

💉
9 new vaccine product forecasts

Volume and value forecasts to 2040 for 9 new and emerging products spanning ETEC, Lyme, Zika, Campylobacter, Shigella, norovirus and malaria, under three IATA-anchored scenarios. Split by traveller type: Visiting Friends & Relatives (VFR) and Business + Other.

✈️
Traveller behaviour analysis

Full review of traveller types, travel behaviour patterns, post-pandemic recovery trajectory and the implications for vaccine uptake. VFR travellers versus business and leisure - two very different vaccination compliance profiles.

⚖️
Recommendations & mandatory requirements

Full review of CDC, WHO and country-level travel vaccine recommendations post-pandemic. IHR mandatory vaccines (yellow fever, meningococcal, polio) assessed alongside the evolving recommended vaccine landscape.

Sample analysis

A glimpse of the market model

The table below shows a partial view of the new vaccine product forecast framework. The full 169-cell marketed-vaccine build, absolute values, country splits, confidence grades and the three forecast scenarios are in the licensed workbooks.

Vaccine / indication Developer Traveller type Status (2026) Forecast included
IXCHIQ (chikungunya)Valneva SEAll traveller typesApproved (FDA)Yes - 14 markets
Dengue (Qdenga)Takeda / partnersAll traveller typesApproved (EU, selected)Yes - 14 markets
TBE (new forecast)Pfizer / BaxterEuropean/Asian travelEstablished + expandingYes - new addition
███████ (ETEC)████████VFR + leisureLate-stage$██m (base 2030)
███████ (Lyme)████████Outdoor/adventurePhase 3$██m (base 2030)
Total new vaccinesAllAllMixed$███m (base 2040)
🔒
Full model in the licensed workbooks
169 anchored cells · 13 marketed vaccines · 9 new products · 14 origin countries · three scenarios to 2040
Request access →
Deliverables

What you receive

The most comprehensive independent commercial assessment of the travel vaccine segment available - combining the proprietary de-layering methodology, primary research and fully interactive forecast workbooks. The 2026 edition is complete and now available to order.

  • Executive presentation (>300 slides, PDF) - travel vaccine market overview, indication landscape, company portfolios, traveller behaviour analysis, regulatory review and commercial forecasts with full supporting narrative
  • Two interactive MS-Excel workbooks - existing travel vaccine market quantification (proprietary methodology) plus new vaccine product forecasts to 2040, with 14-country output and traveller type segmentation
  • The 169-cell marketed-vaccine build - 13 marketed travel vaccines de-layered from their wider franchises across 13 origin markets, each cell anchored to disclosed company actuals where they exist, apportioned by pathogen-specific outbound travel and graded for confidence
  • Three IATA-anchored forecast scenarios to 2040 - high, base and low, spanning a 2.9 to 3.3 percent CAGR band, tied to air passenger projections rather than generic tourism growth
  • Licensed-label availability footprint - a traffic-light map of traveller-market availability across the modelling countries, so revenue is only ever allocated where a product can actually be sold
  • Proprietary travel demand dataset - the core output of the new methodology: travel-specific volume and value per indication, separated from endemic and schedule use. This dataset is not available from any other source
  • 9 new vaccine product forecasts - including dengue, chikungunya, ETEC, Lyme and TBE, with volume and value outputs split by VFR and Business + Other traveller type across all 14 origin markets
  • Primary traveller survey (2023 wave) - consumer research with prospective travellers to endemic regions, covering disease awareness, vaccination attitudes and willingness to pay for new travel vaccines, carried into the 2026 edition
  • 2026 edition - the marketed-vaccine market rebuilt bottom-up on the 169-cell structure, dengue and chikungunya reclassified from pipeline to marketed, forecast scenarios re-anchored to current IATA air passenger projections, and the travel-demand outlook updated to Q1 2026
Target audience

Built for organisations where travel vaccine strategy meets commercial intelligence

The traveller base is at a record high and a wave of new vaccines is arriving into it. The opportunity is real - but quantifying it requires travel-attributed data that standard commercial sources simply do not provide, because no manufacturer reports revenue by setting of use.

💊

Travel vaccine manufacturers

Market sizing by origin country and traveller type, competitive benchmarking and new product opportunity assessment across all 14 modelled markets.

📈

Corporate strategy & BD

Independent commercial validation of the new travel vaccine opportunity (dengue, chikungunya, Lyme, ETEC) before licensing, acquisition or pipeline investment decisions.

🏦

Investors & analysts

Rigorous, methodology-transparent market sizing for travel vaccine assets - the only independent analysis that separates travel-specific demand from endemic use, with every country-level cell graded for confidence.

🏥

Travel medicine clinics

Market context and traveller behaviour data to support business planning, counselling protocol development and new vaccine uptake forecasting.

🏛️

Health authorities & policy

Evidence base for travel vaccine recommendation policy across major outbound markets, with consumer attitude data from the primary survey.

📋

Market access & HEOR

Pricing benchmarks, traveller willingness-to-pay data and payer landscape for new travel vaccine submissions across the 14 origin countries.

About this analysis · VAMV090

The VacZine Analytics travel vaccine segment report tackles the fundamental data gap in travel medicine market intelligence: the inability to isolate travel-specific vaccine demand from endemic and schedule use. The 2026 edition is complete and now available to order. It rebuilds the marketed travel vaccine market from the bottom up - 13 vaccines de-layered from their wider franchises across 13 origin markets, 169 country-level cells anchored to disclosed company actuals where they exist and graded for confidence - and re-anchors the forecast scenarios to current IATA air passenger projections out to 2040.

The primary consumer survey - covering prospective travellers' awareness of endemic diseases and attitudes to new vaccines, fielded as the 2023 wave and carried into this edition - provides a layer of demand-side intelligence that no purely model-based analysis can replicate. Two published insights set out the structure of the model and the travel-demand backdrop it runs on: Travel vaccines 2026: the whole arc, one analysis and Global travel 2026: continued growth, emerging headwinds. VAMV090 is one of the most-visited pages in the VacZine Analytics portfolio, reflecting the acute shortage of credible travel vaccine market data.

MarketVIEW · VAMV090 · 2026 Edition · Now Available to Order

License the travel vaccine segment forecast

The 2026 edition is complete and available to order now, with the 169-cell marketed-vaccine build, 9 new product forecasts and three IATA-anchored scenarios to 2040. Contact VacZine Analytics for pricing, sample slides and licensing terms. Single-licence and multi-user options available, and a briefing call is included on request.